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~ Neonatal screening program for cystic fibrosis (CF) in Minas 
Gerais, Brazil 
F.J.C. Reis, S.O. Mela, A.A. Vergara. CF Cente~ General Center of 
Pediatrics (CGP), Belo Horizonte, Minas Gerais (MG), Brazil 
The natianal neanatal screening pragram far CF was started in MG State, Brazil, an 
01/07/2003. Until 30/04/2005 455,755 newbarn babies (NB) were screened (96% 
af all NB in MG), with the identificatian af 53 CF patients. The aim af the study 
was the analysis af the clinical and labaratarial evalutian af the 30 NB diagnased 
during the first year af screening. 
Methods: Data analyzed fram the 30 NB diagnased fram 01/07/2003 ta 30/06/2004: 
a) at the diagnasis: age, IRT values, AF508, sweat tests, weight (W) and height 
(H), edema, albuminemia, nemia, pancreatic status and Shwachman scare (SS); 
b) at 6 and 12 manths af age: W and H, SS, number af admissians ta haspital, 
Pseudamanas eruginasa (Pa) calanizatian, umber af deaths. 
Results: At the diagnasis: the median age at the diagnasis was 51.4 (32 100) days. 
Median IRTs were 192ng/dl (1st) and 179ng/dl (2nd). Sweat tests (2 samples) 
were all > 90 mmal/1. AF508 was present in 33.3% af alleles. The median W was 
3808 g and H was 53.3 cm. Anemia (Hb < 10 g/dl) was present in 50% af patients 
and hypaalbuminemia (<3 g/dl) in 60% af patients. 23.3% af them had edema 
and severe hypaalbuminemia (< 2.1 g/dl). 79.4% had pancreatic nsufficiency. The 
median SS was 86.7. At 6m and 12m af age: The median W was 6.479g and 
8.872 g respectively. The median H was 64 cm and 73 cm. The median SS was 
86.5 and 85.1. 11 patients were admitted in 19 accasians in the first 6 manths af 
age. 7/30 (23.3%) patients were admitted ta an ICU in 8 accasians. 8/30 (26.6%) 
patients were calanized with Pa. 
Conclusion: The neanatal screening pragram far CF has shawn the severity af 
clinical manifestatians i  23.3% af patients belaw ane year af age. Many af these 
patients wauld have been died withaut he diagnasis af CE 
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~ Nanoduct ® sweat conductivity measurements in 1000 subjects 
M-C. Desax 1, J. Barben 3, J. Hammer 2, R.A. Ammann 1 , M.H. Schaeni 1. 
1Departments of Pediatrics' University of Berne; 2 University of Basel; 
3pulmonology, Children ~' Hospital, St. Gallen, Switzeffand 
Sweat chlaride cancentratian is the current diagnastic gald standard far Cystic 
Fibrasis (CF). Nanaduct ® is an analysis system far sweat canductivity which 
requires 3gl af sweat and gives results within 30 minutes. 
Aim: We tested Nanaduct ® in 3 children's haspitals and campared incanclusive 
results with chlaride (Macraduct ® call system, ar Gibsan and Caake). 
Method: We did Nanaduct ®tests in 1000 subjects: 66 newbarns, 934 > 1 manth, 
33 > 20 years ald. 
Results: In 1000 subjects we abtained canclusive results in 905; in 95 the test failed 
due ta law sweat rate ar technical prablems (9.5% failure). This was mainly due ta 
the high failure rate in newbarns (53%). 46 test were dane in CF patients: 17 were 
previausly knawn and 29 were newly diagnased. Assuming 54 mmal/1 as upper limit 
af narmal 64/954 were false pasitive (6.7%); setting this limit at 59 mmal/1 resulted 
in 39/954 false pasitive results (4.1%). CF patients had a median canductivity af 
115mmal/1 (range 60 139); the nan-CF, including the false pasitives, a median 
af 37mmal/1 (range 2 108). 288 subjects were tested with bath Nanaduct ® and 
Macraduct ®. Nanaduct ®had a lawer failure rate (6.3% vs. 18.4%, p < 0.001). Its 
sensitivity ta detect CF was 100% (95%CI, 88 ta 100), and specificity was 88% 
(95% CI, 84 ta 92), with an area under the ROC curve af 0.996. 
Conclusions: The Nanaduct ® test is a reliable diagnastic taal far CF diagnasis. 
It has a lawer failure rate than the canventianal sweat ests and can be used as a 
simple bedside test far fast and reliable exclusian, diagnasis ar suspician af CE In 
cases with barderline canductivity values ather additianal methads (determinatian 
af chlaride and genatyping) are indicated. 
• Comparison of two sweat test methods in well infants at 
5-6 weeks of age 
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Background: Sweat testing at 5 6 weeks af age is a key component af newborn 
screening far CE There are a lack af normal data far sweat electrolytes in these 
infants and a traditional sweat test method (Gibson Cooke (GC)) is becoming 
obsolete. 
Aims and Method: Twa sweat est methods were compared (1) collection onto 
filter paper followed by analysis by flame photometry and caulametry (GC method) 
and (2) collection through capillary action (Macraduct method) and ian selective 
electrode analysis. Consent was obtained in the postnatal period and the twa 
methods undertaken at5 6 weeks af age. Sweat ests were performed consecutively 
an the outer thigh, in a random sequence. Sweat was collected according ta 
Association af Clinical Biochemistry (UK) protocol and analysed within 48 hours. 
Results: 89 families were visited. In eight cases insufficient sweat was collected by 
method (2), in four cases by method (1) and in four cases by both methods. A "Bland 
Altman" plot was constructed examining average sweat electrolyte concentration 
versus difference between the twa methods. Good limits af agreement are shown 
between the twa methods far both Na+ and C1 concentration. The macraduct 
method consistently reads higher ian concentrations (average 4.7 mmal/1, Na+ and 
1.8, C1 ) although nat clinically significant. 
Conclusion: Sweat esting at 5 6 weeks af age is challenging. These data suggest 
the Macraduct system can be used far sweat collection as a replacement far the 
"Gibson Cooke" method. Further data will be collected ta determine a normal range 
in 5 6 week ald infants. 
I •  Sweat conductivity measurement with Macroduct ® coil system 
for Cystic Fibrosis 
G. Cinel, N. Gurcan, D. Dagru, E. Yalcin, N. Cabanaglu, S. Pekcan, U. Ozcelik, 
N. Kiper. Pediatric Pulmonology Unit, Hacettepe University Medical School, 
Ankara, Turkey 
Introduction: Measurement af sweat chlaride cancentratian, as described by 
Gibsan and Caake, has been the mast widely used diagnastic test far cystic fibrasis 
(CF) far many years. This pracedure invalves multiple steps far callectian and 
analysis and is nat easy ta perfarm. It alsa has the risk af valumetric, gravimetric, 
candensatian d evaparatian errars, especially in labarataries that da nat perfarm 
this test rautinely. Sa new methads are develaped far sweat esting which are easier 
ta perfarm. One af these methads i  canductivity measurement with Macraduct ®
call system which is nat yet appraved as a definitive diagnastic taal far CE 
Aim: Ta assess the capacity af sweat canductivity a discriminate between CF and 
nan-CF subjects. 
Method: 59 CF patients, 75 nan-CF cantral graup were tested. Sweat tests were 
perfarmed using the Macraduct ® canductivity system and measurement af sweat 
chlaride cancentratian with standard Gibsan Caake technique simultaneausly an 
the right and left arms. 
Results: Canductivity mean values in CF and nan-CF subjects were 120mmal/1 
and 43 mmal/1, respectively. The best canductivity cut-affvalue ta diagnase CF was 
~> 90 mmal/1 (sensitivity 92.9%, specificity 100%, pasitive and negative predictive 
values af 100% and 94.4%, respectively and ~; 0.934). Likewise, the best can- 
ductivity cut-aff value ta exclude CF was 70 mmal/1. (sensitivity 93.4%, specificity 
92.1%, pasitive and negative predictive values af 91.9% and 93.5%, respectively 
and I; 0.855). 
Conclusion: Sweat canductivity measurement with Macraduct ® call system is 
successful ta discriminate between CF and nan-CF subjects. As it's easy ta perfarm 
and decreases the technical errars; it can be widely used as a screening test far CE 
